LGD 3303 Capsules

Product Details LGD-3303 is an investigational compound classified within the category of selective androgen receptor modulators (SARMs). It is typically examined in controlled laboratory environments for its interaction with androgen receptor signaling pathways. The compound is provided in a contained format designed to maintain stability and protect the material from external environmental factors. Current research focuses on its structural characteristics and receptor-binding properties at the molecular level. Rather than emphasizing outcomes, ongoing investigations explore how LGD-3303 interacts with intracellular signaling systems associated with androgen receptor activity and downstream transcription processes. Mechanism of Action LGD-3303 is studied for its selective binding affinity to androgen receptors. These receptors function as ligand-activated transcription factors that regulate gene expression following activation. Upon interaction with the androgen receptor, LGD-3303 is analyzed for its role in modulating receptor conformation and influencing cofactor recruitment. This process contributes to changes in gene transcription patterns associated with androgen-responsive elements. Additionally, its selectivity is a key focus in research, particularly in understanding how receptor-specific binding may influence signaling pathways without broadly activating unrelated receptor systems. These investigations are conducted at the molecular and cellular levels to better characterize receptor-ligand dynamics. Chemical Properties Property LGD-3303 Molecular Formula C16H14ClF3N2O IUPAC Name 9-chloro-2-ethyl-1-methyl-3-(2,2,2-trifluoroethyl)-6H-pyrrolo[3,2-f]quinolin-7-one Molecular Mass 342.74 g/mol CAS Number 917891-35-1 PubChem CID 25195253 Shelf Life 36 months Research Applications Androgen Receptor Binding Studies LGD-3303 is commonly utilized in studies examining androgen receptor-ligand interactions. These investigations focus on receptor selectivity, binding affinity, and conformational changes following ligand association. Gene Expression and Transcriptional Activity Analysis Research involving LGD-3303 often explores its role in androgen-responsive gene transcription. This includes evaluating how receptor activation influences downstream signaling cascades at the genomic level. Receptor Selectivity and Signal Modulation Another area of interest involves analyzing selective receptor modulation. Studies aim to understand how targeted receptor interaction affects signaling specificity within complex cellular systems. Why Choose BehemothLabz to Buy LGD-3303 Capsules for Research BehemothLabz provides research-grade LGD-3303 Capsules manufactured under controlled laboratory conditions with strict quality assurance protocols. Each batch undergoes analytical verification to ensure consistency in molecular composition and purity. Comprehensive documentation, including laboratory testing reports and sourcing transparency, supports reproducibility in experimental settings. BehemothLabz maintains a compliance-focused approach, supplying compounds intended strictly for laboratory-based investigation and analytical research Disclaimer LGD-3303 Capsules are intended strictly for laboratory research and analytical purposes only. It is not intended for use in diagnostic procedures, therapeutic applications, or in vivo studies of any kind. Any references to biochemical pathways, receptor interactions, or enzymatic processes are provided solely for informational and research-context purposes. This compound must be handled exclusively by qualified professionals in controlled laboratory environments in accordance with applicable regulations and safety guidelines. Improper handling or use outside of controlled research settings is strictly prohibited. References Gadaj, A., Ventura, E., Ripoche, A., & Mooney, M. H. (2019). Monitoring of selective androgen receptor modulators in bovine muscle tissue by ultra-high performance liquid chromatography-tandem mass spectrometry. Food chemistry: X, 4, 100056. https://doi.org/10.1016/j.fochx.2019.100056 Broberg, M. N., Knych, H., Bondesson, U., Pettersson, C., Tidstedt, B., Stanley, S., Thevis, M., & Hedeland, M. (2023). Equine in vivo metabolite profiling of the selective androgen receptor modulator LGD-3303 for doping control. Journal of pharmaceutical and biomedical analysis, 233, 115468. https://doi.org/10.1016/j.jpba.2023.115468